Overview
Dr. Driscoll participates in:
-multi-institutional studies for the treatment of high risk neuroblastoma patients using high dose chemotherapy with stem cell transplant and the development of new therapies for high risk neuroblastoma patients.
-Cellular therapies, including Tisagenlecleucel for CD19(+) B-cell ALL and gene therapy for patients with Sickle Cell Disease.
-multi-institutional studies for the treatment of high risk neuroblastoma patients using high dose chemotherapy with stem cell transplant and the development of new therapies for high risk neuroblastoma patients.
-Cellular therapies, including Tisagenlecleucel for CD19(+) B-cell ALL and gene therapy for patients with Sickle Cell Disease.
Current Duke Appointments & Affiliations
Associate Professor of Pediatrics
·
2024 - Present
Pediatrics, Transplant and Cellular Therapy,
Pediatrics
Recent Scholarly Works
Long-Term Clinical Outcomes of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory ALL.
Journal article J Clin Oncol · July 29, 2026 We report the 5-year analysis of tisagenlecleucel in 79 pediatric and young adult patients with relapsed or refractory (r/r) B-cell ALL (B-ALL) from the global phase II ELIANA trial (ClinicalTrials.gov identifier: NCT02435849), with a median follow-up of 7 ... Full text Link to item CiteAutologous stem cell transplant for severe, progressive juvenile systemic sclerosis.
Journal article Stem Cells Transl Med · March 23, 2026 Juvenile systemic sclerosis (jSSc) is a rare, chronic, autoimmune disease in children/adolescents and is associated with significant morbidity, skin thickening/hardening (scleroderma), organ toxicity and sub-optimal therapeutic options. In this report, aut ... Full text Link to item CitePre-transplant immunosuppression in pediatric patients undergoing haploidentical stem cell transplant for sickle cell disease is associated with positive outcomes.
Journal article Bone Marrow Transplant · February 2026 Full text Link to item CiteRecent Grants
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis or Invasive Mucormycosis in Pediatric Subjects
Clinical TrialPrincipal Investigator · Awarded by Astellas Pharma Global Development, Inc · 2020 - 2024A multicenter study of apheresis collection of peripheral blood mononuclear (PBMC) in patients with CD19 expressing malignancies who could be eligible for a CTL019 clinical research trial
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2015 - 2020Acid Sphingomyelinase Activation in Apoptosis
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1997 - 2002View All Grants
Education
Ohio State University ·
1990
M.D.